CPHINYSEPharmaceutical PreparationsFiscal year ends December 31
CHINA PHARMA HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.69−0.02 (-3.49%)
Close on Oct 19, 2026
- Market cap
- $27.76M
- P/E (TTM)
- –
- Dividend yield
- –
CHINA PHARMA HOLDINGS, INC. revenue by segment
By business segment
| Revenue | Q4 21 | Q3 21 | Q2 21 | Q4 20 | Q3 20 | Q2 20 | Q4 19 | Q3 19 | Q2 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Domestic Pharmaceuticals [Member] | $2.89M | $1.98M | $2.42M | $2.90M | $2.40M | $2.07M | $3.05M | $2.38M | $2.57M | 100.0% | -0.3% |
| Export Medical Test Kits [Member] | – | – | – | – | $0 | $1.70M | – | – | – | – | – |
| Export Medical Test Kits [Member] | – | – | – | $33.13K | $0 | $1.70M | – | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of China Pharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.